Jeito Capital, an independent Private Equity fund specialising in biopharma, is leading a USD 65 million (approx. £47 million) Series A financing round in ReproNovo. The company is developing innovative treatments for reproductive medicine and women’s health. ReproNovo aims to address significant gaps in reproductive medicine, including male and female infertility, and uterine health. The company will use the financing to advance two Phase 2 clinical-stage assets. The lead candidate, RPN-001 (leflutrozole), will focus on the development of an oral therapy for male infertility due to low testosterone levels. The other candidate, RPN-002 (nolasiban), will be used to manage adenomyosis, a common gynaecological condition, and improve success rates in assisted reproductive technologies (ART).